Novo Nordisk - 42 Year Stock Price History | NVO

Historical daily share price chart and data for Novo Nordisk since 1982 adjusted for splits and dividends. The latest closing stock price for Novo Nordisk as of February 29, 2024 is 119.77.
  • The all-time high Novo Nordisk stock closing price was 124.52 on February 22, 2024.
  • The Novo Nordisk 52-week high stock price is 124.86, which is 4.2% above the current share price.
  • The Novo Nordisk 52-week low stock price is 67.66, which is 43.5% below the current share price.
  • The average Novo Nordisk stock price for the last 52 weeks is 92.25.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Novo Nordisk Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 113.5588 102.1100 124.5200 102.1100 119.7700 15.78%
2023 84.6105 67.6312 105.4500 65.3498 103.4500 54.79%
2022 53.7965 52.9255 66.8312 45.2925 66.8312 22.65%
2021 42.9198 34.1020 56.9585 32.0157 54.4872 63.39%
2020 30.7187 27.2683 35.2335 23.1099 33.3477 23.31%
2019 23.7797 21.6738 27.2216 21.4746 27.0441 26.73%
2018 22.1363 24.4394 26.2354 19.2419 21.3403 -11.88%
2017 19.1492 15.7231 24.2454 14.4362 24.2183 54.29%
2016 21.0310 24.4110 24.9303 13.8190 15.6968 -36.56%
2015 22.7920 17.8315 25.6592 17.5839 24.7433 39.32%
2014 18.5554 15.1249 20.5761 15.1249 17.7602 16.69%
2013 14.0149 13.3997 15.6954 12.4015 15.2196 15.44%
2012 11.8539 9.2843 13.7414 9.1652 13.1840 44.10%
2011 9.1516 8.6980 10.4329 7.5078 9.1494 3.90%
2010 6.7115 5.0442 8.8059 4.9450 8.8059 79.47%
2009 4.3089 3.9700 5.3277 3.2252 4.9066 27.03%
2008 4.5132 4.7343 5.4890 3.3086 3.8625 -19.75%
2007 3.9382 3.0524 5.0497 3.0081 4.8130 57.36%
2006 2.4522 2.0476 3.0849 1.9753 3.0586 51.05%
2005 1.9093 1.8791 2.1544 1.7450 2.0249 5.26%
2004 1.7409 1.4389 1.9504 1.3674 1.9238 34.62%
2003 1.2136 1.0099 1.4291 0.8708 1.4291 43.95%
2002 1.0867 1.3643 1.3947 0.7664 0.9928 -27.23%
2001 1.3690 1.2008 1.5729 1.1806 1.3643 14.18%
2000 1.1594 0.9020 1.5203 0.8308 1.1949 37.85%
1999 0.7770 0.9295 0.9295 0.6426 0.8668 -2.00%
1998 0.9317 0.9441 1.1257 0.7200 0.8845 -7.45%
1997 0.7102 0.5935 0.9573 0.5803 0.9557 55.00%
1996 0.4873 0.4591 0.6247 0.4180 0.6166 37.27%
1995 0.3638 0.3043 0.4492 0.2946 0.4492 45.33%
1994 0.3244 0.3206 0.3579 0.2864 0.3091 -3.59%
1993 0.2885 0.2840 0.3206 0.2526 0.3206 12.25%
1992 0.2832 0.2901 0.3098 0.2558 0.2856 -0.17%
1991 0.2241 0.1975 0.2957 0.1808 0.2861 44.64%
1990 0.1632 0.1560 0.2034 0.1400 0.1978 25.91%
1989 0.1380 0.1202 0.1630 0.1202 0.1571 30.70%
1988 0.1004 0.0704 0.1295 0.0704 0.1202 84.64%
1987 0.1018 0.0998 0.1261 0.0613 0.0651 -34.31%
1986 0.0927 0.0865 0.1036 0.0794 0.0991 13.13%
1985 0.0839 0.0708 0.1036 0.0690 0.0876 23.73%
1984 0.1247 0.1689 0.1823 0.0641 0.0708 -57.60%
1983 0.1745 0.1264 0.2169 0.1264 0.1670 27.68%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $545.415B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $719.883B 119.88
Johnson & Johnson (JNJ) United States $389.136B 15.49
Merck (MRK) United States $324.660B 85.46
AbbVie (ABBV) United States $314.432B 16.02
Novartis AG (NVS) Switzerland $216.666B 15.01
AstraZeneca (AZN) United Kingdom $202.610B 17.95
Pfizer (PFE) United States $152.689B 14.78
Sanofi (SNY) $121.420B 10.93
Innoviva (INVA) United States $0.984B 8.87